This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kovtun, Y. V. Articles by Goldmacher, V. S. Search for Related Content PubMed PubMed Citation Articles by Kovtun, Y. V. Articles by Goldmacher, V. S.

Antibody-Drug Conjugates Designed to Eradicate Tumors with Homogeneous and Heterogeneous Expression of the Target Antigen

ImmunoGen, Inc., Cambridge, Massachusetts

Requests for reprints: Yelena V. Kovtun, ImmunoGen, Inc., 128 Sidney Street, Cambridge, MA 02139. Phone: 617-995-4917; Fax: 617-995-2510; E-mail: yelena.kovtun{at}immunogen.com.

Conjugates of the anti-CanAg humanized monoclonal antibody huC242 with the microtubule-formation inhibitor DM1 (a maytansinoid), or with the DNA alkylator DC1 (a CC1065 analogue), have been evaluated for their ability to eradicate mixed cell populations formed from CanAg-positive and CanAg-negative cells in culture and in xenograft tumors in mice. We found that in culture, conjugates of either drug killed not only the target antigen-positive cells but also the neighboring antigen-negative cells. Furthermore, we showed that, in vivo, these conjugates were effective in eradicating tumors containing both antigen-positive and antigen-negative cells. The presence of antigen-positive cells was required for this killing of bystander cells. This target cell–activated killing of bystander cells was dependent on the nature of the linker between the antibody and the drug. Conjugates linked via a reducible disulfide bond were capable of exerting the bystander effect whereas equally potent conjugates linked via a nonreducible thioether bond were not. Our data offer a rationale for developing optimally constructed antibody-drug conjugates for treating tumors that express the target antigen either in a homogeneous or heterogeneous manner. (Cancer Res 2006; 66(6): 3214-21)

This article has been cited by other articles:

				N. M. Okeley, J. B. Miyamoto, X. Zhang, R. J. Sanderson, D. R. Benjamin, E. L. Sievers, P. D. Senter, and S. C. Alley Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate Clin. Cancer Res., February 1, 2010; 16(3): 888 - 897. [Abstract] [Full Text] [PDF]

				B. Zheng, R. N. Fuji, K. Elkins, S.-F. Yu, F. K. Fuh, J. Chuh, C. Tan, J.-A. Hongo, H. Raab, K. R. Kozak, et al. In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates Mol. Cancer Ther., October 1, 2009; 8(10): 2937 - 2946. [Abstract] [Full Text] [PDF]

				A. M. Al-Katib, A. Aboukameel, R. Mohammad, M.-C. Bissery, and C. Zuany-Amorim Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma Clin. Cancer Res., June 15, 2009; 15(12): 4038 - 4045. [Abstract] [Full Text] [PDF]

				H. Ikeda, T. Hideshima, M. Fulciniti, R. J. Lutz, H. Yasui, Y. Okawa, T. Kiziltepe, S. Vallet, S. Pozzi, L. Santo, et al. The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo Clin. Cancer Res., June 15, 2009; 15(12): 4028 - 4037. [Abstract] [Full Text] [PDF]

				A. G. Polson, J. Calemine-Fenaux, P. Chan, W. Chang, E. Christensen, S. Clark, F. J. de Sauvage, D. Eaton, K. Elkins, J. M. Elliott, et al. Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection Cancer Res., March 15, 2009; 69(6): 2358 - 2364. [Abstract] [Full Text] [PDF]

				G. D. Lewis Phillips, G. Li, D. L. Dugger, L. M. Crocker, K. L. Parsons, E. Mai, W. A. Blattler, J. M. Lambert, R. V.J. Chari, R. J. Lutz, et al. Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate Cancer Res., November 15, 2008; 68(22): 9280 - 9290. [Abstract] [Full Text] [PDF]

				E. Oflazoglu, I. J. Stone, K. Gordon, C. G. Wood, E. A. Repasky, I. S. Grewal, C.-L. Law, and H.-P. Gerber Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker Clin. Cancer Res., October 1, 2008; 14(19): 6171 - 6180. [Abstract] [Full Text] [PDF]

				E. Ostermann, P. Garin-Chesa, K. H. Heider, M. Kalat, H. Lamche, C. Puri, D. Kerjaschki, W. J. Rettig, and G. R. Adolf Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts Clin. Cancer Res., July 15, 2008; 14(14): 4584 - 4592. [Abstract] [Full Text] [PDF]

				M. D. Galsky, M. Eisenberger, S. Moore-Cooper, W. K. Kelly, S. F. Slovin, A. DeLaCruz, Y. Lee, I. J. Webb, and H. I. Scher Phase I Trial of the Prostate-Specific Membrane Antigen-Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer J. Clin. Oncol., May 1, 2008; 26(13): 2147 - 2154. [Abstract] [Full Text] [PDF]

				A. G. Polson, S.-F. Yu, K. Elkins, B. Zheng, S. Clark, G. S. Ingle, D. S. Slaga, L. Giere, C. Du, C. Tan, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma Blood, July 15, 2007; 110(2): 616 - 623. [Abstract] [Full Text] [PDF]

				Q. Chen, H. J. Millar, F. L. McCabe, C. D. Manning, R. Steeves, K. Lai, B. Kellogg, R. J. Lutz, M. Trikha, M. T. Nakada, et al. {alpha}v Integrin-Targeted Immunoconjugates Regress Established Human Tumors in Xenograft Models Clin. Cancer Res., June 15, 2007; 13(12): 3689 - 3695. [Abstract] [Full Text] [PDF]

				Y. Chen, S. Clark, T. Wong, Y. Chen, Y. Chen, M. S. Dennis, E. Luis, F. Zhong, S. Bheddah, H. Koeppen, et al. Armed Antibodies Targeting the Mucin Repeats of the Ovarian Cancer Antigen, MUC16, Are Highly Efficacious in Animal Tumor Models Cancer Res., May 15, 2007; 67(10): 4924 - 4932. [Abstract] [Full Text] [PDF]

				L. M. Smith, A. Nesterova, S. C. Alley, M. Y. Torgov, and P. J. Carter Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Mol. Cancer Ther., June 1, 2006; 5(6): 1474 - 1482. [Abstract] [Full Text] [PDF]

				H. K. Erickson, P. U. Park, W. C. Widdison, Y. V. Kovtun, L. M. Garrett, K. Hoffman, R. J. Lutz, V. S. Goldmacher, and W. A. Blattler Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res., April 15, 2006; 66(8): 4426 - 4433. [Abstract] [Full Text] [PDF]